Cargando…

Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia

Proteasome inhibitors significantly improve cancer outcomes, but their use is eventually followed by proteasome inhibitor resistance and relapse. Current understanding of proteasome inhibitor resistance is limited to cell‐autonomous mechanisms; whether non–autonomous mechanisms can be implicated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Maolin, Qiao, Zhi, Kong, Yan, Lu, Hui, Liu, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156829/
https://www.ncbi.nlm.nih.gov/pubmed/32058648
http://dx.doi.org/10.1111/cas.14351
_version_ 1783522295845748736
author Ge, Maolin
Qiao, Zhi
Kong, Yan
Lu, Hui
Liu, Han
author_facet Ge, Maolin
Qiao, Zhi
Kong, Yan
Lu, Hui
Liu, Han
author_sort Ge, Maolin
collection PubMed
description Proteasome inhibitors significantly improve cancer outcomes, but their use is eventually followed by proteasome inhibitor resistance and relapse. Current understanding of proteasome inhibitor resistance is limited to cell‐autonomous mechanisms; whether non–autonomous mechanisms can be implicated in the development of proteasome inhibitor resistance is unclear. Here, we show that proteasome inhibitor tolerance can be transmitted non–autonomously through exosome‐mediated intercellular interactions. We revealed that reversible proteasome inhibitor resistance can be transmitted from cells under therapy stress to naïve sensitive cells through exosome‐mediated cell cycle arrest and enhanced stemness in mixed‐lineage leukemia cells. Integrated multi‐omics analysis using the Tied Diffusion through Interacting Events algorithm identified several candidate exosomal proteins that may serve as predictors for proteasome inhibitor resistance and potential therapeutic targets for treating refractory mixed‐lineage leukemia. Furthermore, inhibiting the secretion of exosomes is a promising strategy for reversing proteasome inhibitor resistance in vivo, which provides a novel proof of principle for the treatment of other refractory or relapsed cancers.
format Online
Article
Text
id pubmed-7156829
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71568292020-04-20 Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia Ge, Maolin Qiao, Zhi Kong, Yan Lu, Hui Liu, Han Cancer Sci Original Articles Proteasome inhibitors significantly improve cancer outcomes, but their use is eventually followed by proteasome inhibitor resistance and relapse. Current understanding of proteasome inhibitor resistance is limited to cell‐autonomous mechanisms; whether non–autonomous mechanisms can be implicated in the development of proteasome inhibitor resistance is unclear. Here, we show that proteasome inhibitor tolerance can be transmitted non–autonomously through exosome‐mediated intercellular interactions. We revealed that reversible proteasome inhibitor resistance can be transmitted from cells under therapy stress to naïve sensitive cells through exosome‐mediated cell cycle arrest and enhanced stemness in mixed‐lineage leukemia cells. Integrated multi‐omics analysis using the Tied Diffusion through Interacting Events algorithm identified several candidate exosomal proteins that may serve as predictors for proteasome inhibitor resistance and potential therapeutic targets for treating refractory mixed‐lineage leukemia. Furthermore, inhibiting the secretion of exosomes is a promising strategy for reversing proteasome inhibitor resistance in vivo, which provides a novel proof of principle for the treatment of other refractory or relapsed cancers. John Wiley and Sons Inc. 2020-03-10 2020-04 /pmc/articles/PMC7156829/ /pubmed/32058648 http://dx.doi.org/10.1111/cas.14351 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ge, Maolin
Qiao, Zhi
Kong, Yan
Lu, Hui
Liu, Han
Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title_full Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title_fullStr Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title_full_unstemmed Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title_short Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
title_sort exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156829/
https://www.ncbi.nlm.nih.gov/pubmed/32058648
http://dx.doi.org/10.1111/cas.14351
work_keys_str_mv AT gemaolin exosomesmediateintercellulartransferofnonautonomoustolerancetoproteasomeinhibitorsinmixedlineageleukemia
AT qiaozhi exosomesmediateintercellulartransferofnonautonomoustolerancetoproteasomeinhibitorsinmixedlineageleukemia
AT kongyan exosomesmediateintercellulartransferofnonautonomoustolerancetoproteasomeinhibitorsinmixedlineageleukemia
AT luhui exosomesmediateintercellulartransferofnonautonomoustolerancetoproteasomeinhibitorsinmixedlineageleukemia
AT liuhan exosomesmediateintercellulartransferofnonautonomoustolerancetoproteasomeinhibitorsinmixedlineageleukemia